Tetra Radar · FDA Approvals · Decision date

ulixacaltamide: FDA decision date

Praxis Precision Medicines, Inc. (PRAX) · 29 January 2027

The New Drug Application (NDA) for ulixacaltamide remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of January 29, 2027.

Source: 8-K of 9 November 2026

The decision is pending.

A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.

Get the Dispatch free.